Introduction: Natural product-based drug discovery in Immunopharmacology (original) (raw)
The new era of biological treatments
Doron Rimar
PubMed, 2014
View PDFchevron_right
Biotherapeutics–Current Status and Future Directions
James E Talmadge
View PDFchevron_right
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
Chen-Ni Chin, Ningyan Zhang
Therapeutic Monoclonal Antibodies, 2009
View PDFchevron_right
Development of therapeutic antibodies for the treatment of diseases
Yu-Chyi Hwang
Journal of Biomedical Science, 2020
View PDFchevron_right
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
Curtis Maier, Daniel Wierda
Regulatory Toxicology and Pharmacology Rtp, 2009
View PDFchevron_right
The Immune System as Drug Target
Darren Flower
Immunology and Immunogenetics Insights, 2013
View PDFchevron_right
Pharmaceutical applications of biotechnology: promise and reality Editorial overview On to development and commercialization
Đông Kiều
View PDFchevron_right
Pharmaceutical applications of biotechnology: Promise and reality. Editorial overview
Walter Moos
Current Opinion in Biotechnology, 1993
View PDFchevron_right
A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
Joanne Jones
The Journal of Immunology, 2010
View PDFchevron_right
Innovative Therapy, Monoclonal Antibodies and Beyond
Matteo Bellone
Cytokine & Growth Factor Reviews, 2017
View PDFchevron_right
Global survey of the immunomodulatory potential of common drugs
Monika Sabler
Nature chemical biology, 2017
View PDFchevron_right
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: Recommendations of the innovative medicines initiative ABIRISK consortium
ENRICO MAGGI
Clinical & Experimental Immunology, 2015
View PDFchevron_right
FDA Approvals of Biologics in 2022
Alexander C Martins
Biomedicines
View PDFchevron_right
The international international journal journal for timely for timely in-depth reviews in in-depth reviews in Pharmaceutical Pharmaceutical Biotechnology Biotechnology
Michele M Luchetti
View PDFchevron_right
IMMUNOGENICITY IN PRECLINICAL DRUG DEVELOPMENT: STRATEGIES, RISKS, AND IMPLICATIONS FOR LARGE MOLECULE-BASED BIOLOGICS INCLUDING CAR T-CELL AND GENE THERAPIES
Ashok H Akabari
Journal of Population Therapeutics & Clinical Pharmacology, 2023
View PDFchevron_right
Technological Evolution in the Development of Therapeutic Antibodies
Hugo Barrera-saldaña
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
View PDFchevron_right
Biotechnology products in cancer therapy: a colloquium
Fred fox
Cancer research, 1988
View PDFchevron_right
Prospective new biological therapies for rheumatoid arthritis
Ladislav Senolt
Autoimmunity Reviews, 2009
View PDFchevron_right
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
Syed Husain
Journal for ImmunoTherapy of Cancer, 2013
View PDFchevron_right
Assessing the Immunogenicity of Biopharmaceuticals
Daniel Alvarez
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2016
View PDFchevron_right
Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
miguel gutierrez
Joint Bone Spine, 2014
View PDFchevron_right
Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development
Charles Oo
Expert review of clinical pharmacology, 2016
View PDFchevron_right
The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences
Mauro Keiserman, R. Handa
Expert Review of Clinical Immunology, 2014
View PDFchevron_right
Special Review: The future of Immunotherapy
Cornelis Melief
Immunotherapy Advances, 2020
View PDFchevron_right
The 2005 International Symposium on Advances in Targeted Therapies: What have we learned in the 2000s and where are we going?
Ravinder Maini
Annals of the Rheumatic Diseases, 2005
View PDFchevron_right
Therapeutics discovery: From bench to first in-human trials
Ahmed Alaskar
Biomedical reports, 2018
View PDFchevron_right